Adicet Bio, Inc. (ACET): Shareholders' Equity
$159.21M
As of 2025-12-31
$120.14M
As of 2026-06-30
-18.3%
3-year compound annual growth
+7.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $159.21M | -14.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $186.61M | +9.7% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $170.18M | -41.8% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $292.34M | -3.6% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $303.13M | +176.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $109.83M | n/m | 2023-03-15, Balance as of period end |
| 2019-12-31 | -$60.37M | n/m | 2022-03-15, Balance as of period end |
| 2018-12-31 | -$33.52M | n/c | 2021-03-12, Balance as of period end |
| 2017-12-31 | -$31.93M | n/a | 2020-03-12, Balance as of period end |
| 2016-12-31 | $0 | n/a | 2019-03-18, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $159.21M | -14.7% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $183.24M | +83.9% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$108.50M | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $107.54M | -26.3% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $151.14M | -0.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$105.47M | n/m |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $177.01M | +81.9% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | -$52.85M | n/m |
Compare ACET, TRVI, FHTX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗